Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

832 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B.
Yuen MF, Chen CY, Liu CJ, Jeng WJ, Elkhashab M, Coffin CS, Kim W, Greenbloom S, Ramji A, Lim YS, Kim YJ, Fung SK, Kim DJ, Jang JW, Lee KS, Iyer RP, Macfarlane C, Jackson K, Locarnini SA, Chan HLY, Afdhal NH. Yuen MF, et al. Among authors: lim ys. Liver Int. 2023 Jan;43(1):77-89. doi: 10.1111/liv.15465. Epub 2022 Nov 11. Liver Int. 2023. PMID: 36300646 Clinical Trial.
Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study.
Jun DW, Kim BI, Cho YK, Kim HJ, Kwon YO, Park SY, Han SY, Baek YH, Jung YJ, Kim HY, Kim W, Heo J, Woo HY, Hwang SG, Rim KS, Choi JY, Bae SH, Lee YS, Lim YS, Cheong JY, Cho SW, Lee BS, Kim SH, Sohn JH, Kim TY, Paik YH, Kim JK, Lee KS. Jun DW, et al. Among authors: lim ys. Clin Mol Hepatol. 2013 Jun;19(2):165-72. doi: 10.3350/cmh.2013.19.2.165. Epub 2013 Jun 27. Clin Mol Hepatol. 2013. PMID: 23837141 Free PMC article. Clinical Trial.
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study.
Yuen MF, Lim YS, Yoon KT, Lim TH, Heo J, Tangkijvanich P, Tak WY, Thanawala V, Cloutier D, Mao S, Arizpe A, Cathcart AL, Gupta SV, Hwang C, Gane E. Yuen MF, et al. Among authors: lim ys. Lancet Gastroenterol Hepatol. 2024 Oct 7:S2468-1253(24)00237-1. doi: 10.1016/S2468-1253(24)00237-1. Online ahead of print. Lancet Gastroenterol Hepatol. 2024. PMID: 39389081
Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials.
Buti M, Lim YS, Chan HLY, Agarwal K, Marcellin P, Brunetto MR, Chuang WL, Janssen HLA, Fung SK, Izumi N, Jablkowski MS, Abdurakhmanov D, Abramov F, Wang H, Botros I, Yee LJ, Mateo R, Flaherty JF, Osinusi A, Pan CQ, Shalimar X, Seto WK, Gane EJ. Buti M, et al. Among authors: lim ys. Aliment Pharmacol Ther. 2024 Sep 27. doi: 10.1111/apt.18278. Online ahead of print. Aliment Pharmacol Ther. 2024. PMID: 39327857
Viral Load-Based Prediction of Hepatocellular Carcinoma Risk in Noncirrhotic Patients With Chronic Hepatitis B : A Multinational Study for the Development and External Validation of a New Prognostic Model.
Kim GA, Lim YS, Han S, Choi GH, Choi WM, Choi J, Sinn DH, Paik YH, Lee JH, Lee YB, Cho JY, Heo NY, Yuen MF, Wong VW, Chan SL, Yang HI, Chen CJ. Kim GA, et al. Among authors: lim ys. Ann Intern Med. 2024 Oct;177(10):1308-1318. doi: 10.7326/M24-0384. Epub 2024 Sep 17. Ann Intern Med. 2024. PMID: 39284185
832 results